Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview-Reference-Cited by-同舟云学术

Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview

Published:2024-01 Issue: Volume:193 Page:104195
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Wu Changjin,Li Wentan,Tao Hongyu,Zhang Xiyan,Xin Yu,Song Ruomeng,Wang Kaige,Zuo Ling,Cai Yuanyi,Wu Huazhang,Hui Wen

Funder

Science and Technology Department of Sichuan Province

Department of Education of Liaoning Province

Sichuan Province Science and Technology Support Program

Ministry of Education of the People's Republic of China

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference100 articles.

1. How to carry out a literature search for a systematic review: a practical guide;Atkinson;Brit. J. Psych. Adv.,2018

2. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer;Aziz;J. Med. Econ.,2020

3. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland;Barbier;Eur. J. Health Econ.: HEPAC: Health Econ. Prev. Care,2021

4. Meta-analysis as evidence: building a better pyramid;Berlin;Jama,2014

5. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States;Berling;J. Med. Econ.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China;Frontiers in Public Health;2024-07-18

2. Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study;Clinical and Translational Oncology;2024-06-27